These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 3043160)

  • 1. [Effect of bismuth subsalicylate versus cimetidine on Campylobacter pylori, ulcer healing and rate of recurrence].
    Eberhardt R; Kasper G; Dettmer A; Höchter W; Hagena D
    Med Klin (Munich); 1988 May; 83(12):402-5. PubMed ID: 3043160
    [No Abstract]   [Full Text] [Related]  

  • 2. [Therapy of peptic ulcer and chronic gastritis with bismuth salts].
    Rösch W
    Z Gastroenterol; 1987 Sep; 25 Suppl 4():34-40. PubMed ID: 3687149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of oral bismuth subsalicylate on Campylobacter pylori and on healing and relapse rate of peptic ulcer.
    Eberhardt R; Kasper G
    Rev Infect Dis; 1990; 12 Suppl 1():S115-9. PubMed ID: 2406852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [What is safe in the treatment of Campylobacter pylori-induced gastritis and Campylobacter pylori-associated peptic ulcer?].
    Menge H
    Internist (Berl); 1988 Nov; 29(11):745-54. PubMed ID: 3069787
    [No Abstract]   [Full Text] [Related]  

  • 5. Colloidal bismuth subcitrate (DE-NOL) and tinidazole healed duodenal ulceration with a low relapse rate due to elimination of Campylobacter pylori.
    Goodwin CS; Marshall BJ; Blackbourn SJ; Warren JR; Phillips M
    J Chemother; 1989 Jul; 1(4 Suppl):838-9. PubMed ID: 16312662
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical experience with Campylobacter pylori in western Kentucky.
    Kraus JW; Morello PJ
    J Ky Med Assoc; 1989 Sep; 87(9):448-50. PubMed ID: 2794757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Campylobacter pyloridis is not responsible for duodenal ulcer formation: results of a controlled therapeutic trial.
    Kumar N; Anand BS
    J Assoc Physicians India; 1988 Feb; 36(2):137-9. PubMed ID: 3053613
    [No Abstract]   [Full Text] [Related]  

  • 8. Histological gastritis in duodenal ulcer: relationship to Campylobacter pylori and effect of ulcer therapy.
    Dooley CP; McKenna D; Humphreys H; Bourke S; Keane CT; Sweeney E; O'Morain C
    Am J Gastroenterol; 1988 Mar; 83(3):278-82. PubMed ID: 3344730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of chronic duodenal ulceration. Effectiveness of colloidal bismuth subcitrate tablets compared with cimetidine.
    Harley H; Alp MH
    Med J Aust; 1983 Dec 10-24; 2(12):627-8. PubMed ID: 6366498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Bismuth subsalicylate treatment in chronic Campylobacter pylori-associated erosive gastritis].
    Malfertheiner P; Stanescu A; Baczako K; Vanek E; Bode G; Ditschuneit H
    Dtsch Med Wochenschr; 1988 Jun; 113(23):923-9. PubMed ID: 3378501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparative study of colloidal bismuth subcitrate and cimetidine on the healing and recurrence of duodenal ulcer.
    Vantrappen G; Schuurmans P; Rutgeerts P; Janssens J
    Scand J Gastroenterol Suppl; 1982; 80():23-30. PubMed ID: 6761849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of nitroimidazole resistance in Campylobacter pylori by coadministration of colloidal bismuth subcitrate: clinical and in vitro studies.
    Goodwin CS; Marshall BJ; Blincow ED; Wilson DH; Blackbourn S; Phillips M
    J Clin Pathol; 1988 Feb; 41(2):207-10. PubMed ID: 3280609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Likelihood of relapse of duodenal ulcer after initial treatment with cimetidine or colloidal bismuth subcitrate.
    Miller JP; Hollanders D; Ravenscroft MM; Tweedle DE; Martin DF
    Scand J Gastroenterol Suppl; 1982; 80():39-42. PubMed ID: 6761851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prevention of recurrence with bismuth subsalicylate in a patient with recurrent and H2 receptor antagonist refractory duodenal ulcer].
    Bayerdörffer E; Mannes GA; Pfaller P; Sauerbruch T
    Internist (Berl); 1989 Jun; 30(6):390-2. PubMed ID: 2668217
    [No Abstract]   [Full Text] [Related]  

  • 15. In vivo susceptibility of Campylobacter pylori.
    Graham DY; Klein PD; Opekun AR; Smith KE; Polasani RR; Evans DJ; Evans DG; Alpert LC; Michaletz PA; Yoshimura HH
    Am J Gastroenterol; 1989 Mar; 84(3):233-8. PubMed ID: 2919580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Dose-effect studies with bismuth salts for the elimination of Campylobacter pylori].
    Menge H; Hofmann J; Gregor M
    Z Gastroenterol; 1987 Sep; 25 Suppl 4():44-6. PubMed ID: 3318192
    [No Abstract]   [Full Text] [Related]  

  • 17. [Endoscopic evaluation of a retard cimetidine preparation with reference to its effect in stomach and duodenal ulcer. A comparative study with a non-retard cimetidine preparation].
    Tscheliessnigg KH; Berger A; Mischinger HJ; Kraft-Kinz J
    Wien Med Wochenschr; 1987 Aug; 137(14-15):350-5. PubMed ID: 3314173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparative study of the efficacy of ranitidine, cimetidine (Asiloc), De-Nol and spirulina in the treatment of gastric and duodenal ulcer].
    Fica V; Andronescu D; Olteanu D
    Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna; 1987; 39(1):21-35. PubMed ID: 2884709
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy of tripotassium-dicitrato-bismuthate (TDB) and cimetidine in peptic ulcer disease, a control study of 40 gastric ulcer and 80 duodenal ulcer.
    Chearanai O; Kachintorn U; Plengvanit U
    J Med Assoc Thai; 1987 Apr; 70(4):176-80. PubMed ID: 3612003
    [No Abstract]   [Full Text] [Related]  

  • 20. Monotherapy or polychemotherapy in the treatment of Campylobacter pylori-related gastroduodenal disease.
    Börsch G; Mai U; Müller KM
    Scand J Gastroenterol Suppl; 1988; 142():101-6. PubMed ID: 3166527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.